US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
WO2005016348A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Icos Corporation |
Method of inhibiting immune responses stimulated by an endogenous factor
|
CA2730540A1
(en)
*
|
2004-05-13 |
2005-12-01 |
Vanderbilt University |
Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
|
AU2005245875C1
(en)
|
2004-05-13 |
2017-08-31 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
JP2008520744A
(ja)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
EP1885356A2
(en)
*
|
2005-02-17 |
2008-02-13 |
Icos Corporation |
Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
|
GB2431156A
(en)
*
|
2005-10-11 |
2007-04-18 |
Piramed Ltd |
1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
|
AU2007347115A1
(en)
*
|
2006-04-04 |
2008-10-23 |
The Regents Of The University Of California |
PI3 kinase antagonists
|
JP5313909B2
(ja)
*
|
2006-11-13 |
2013-10-09 |
アイコス コーポレイション |
炎症性疾患および癌の処置のためのチエノピリミジノン
|
EP1953163A1
(en)
|
2007-02-01 |
2008-08-06 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pteridinone derivatives as PI3-kinases inhibitors
|
WO2009002553A1
(en)
*
|
2007-06-25 |
2008-12-31 |
Prolexys Pharmaceuticals, Inc. |
Methods of treating multiple myeloma and resistant cancers
|
FR2918668B1
(fr)
*
|
2007-07-09 |
2009-08-21 |
Arkema France |
Procede ameliore de preparation d'alcoxyamines issues de nitroxydes beta-phosphores.
|
GB2467670B
(en)
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
US20110021541A1
(en)
*
|
2007-11-13 |
2011-01-27 |
White Stephen L |
Inhibitors of human phosphatidyl-inositol 3-kinase delta
|
US8193182B2
(en)
*
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
KR101897881B1
(ko)
*
|
2008-01-04 |
2018-09-12 |
인텔리카인, 엘엘씨 |
특정 화학 물질, 조성물 및 방법
|
RU2537549C2
(ru)
*
|
2008-01-04 |
2015-01-10 |
Интелликайн ЭлЭлСи |
Некоторые химические структуры, композиции и способы
|
AU2014203687B2
(en)
*
|
2008-01-04 |
2016-04-14 |
Intellikine Llc |
Certain chemical entities, compositions and methods
|
US8637542B2
(en)
*
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
WO2009114874A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Benzothiazole kinase inhibitors and methods of use
|
EP2444403A1
(en)
*
|
2008-04-18 |
2012-04-25 |
Shionogi Co., Ltd. |
Heterocyclic compound having inhibitory activity on PI3K
|
JP2011518836A
(ja)
|
2008-04-24 |
2011-06-30 |
インサイト・コーポレイション |
大環状化合物およびそれらのキナーゼ阻害剤としての使用
|
US20110224223A1
(en)
*
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
WO2010012740A1
(en)
*
|
2008-07-29 |
2010-02-04 |
Boehringer Ingelheim International Gmbh |
5-alkynyl-pyrimidines
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
EP2358720B1
(en)
|
2008-10-16 |
2016-03-02 |
The Regents of The University of California |
Fused ring heteroaryl kinase inhibitors
|
US8476282B2
(en)
|
2008-11-03 |
2013-07-02 |
Intellikine Llc |
Benzoxazole kinase inhibitors and methods of use
|
CN102271683B
(zh)
*
|
2008-11-13 |
2014-07-09 |
吉里德卡利斯托加公司 |
恶性血液病的治疗
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
CA2755935A1
(en)
|
2009-02-12 |
2010-08-19 |
Astellas Pharma Inc. |
Hetero ring derivative
|
EA019499B1
(ru)
|
2009-03-24 |
2014-04-30 |
ГИЛИЭД КАЛИСТОГА ЭлЭлСи |
Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения
|
EP2421536B1
(en)
*
|
2009-04-20 |
2015-08-26 |
Gilead Calistoga LLC |
Methods of treatment for solid tumors
|
EP2427195B1
(en)
|
2009-05-07 |
2019-05-01 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
ME01838B
(me)
|
2009-06-29 |
2014-12-20 |
Lncyte Holdings Corp |
Pirimidinoni kao inhibitori pi3k
|
WO2011011550A1
(en)
*
|
2009-07-21 |
2011-01-27 |
Calistoga Pharmaceuticals Inc. |
Treatment of liver disorders with pi3k inhibitors
|
EA026693B1
(ru)
|
2009-08-17 |
2017-05-31 |
Интелликайн ЭлЭлСи |
Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
|
US20110230476A1
(en)
*
|
2009-09-09 |
2011-09-22 |
Avila Therapeutics, Inc. |
Pi3 kinase inhibitors and uses thereof
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
GB0918249D0
(en)
*
|
2009-10-19 |
2009-12-02 |
Respivert Ltd |
Compounds
|
WO2011075643A1
(en)
|
2009-12-18 |
2011-06-23 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as pi3k inhibitors
|
RU2012139182A
(ru)
|
2010-02-22 |
2014-03-27 |
Ф. Хоффманн-Ля Рош Аг |
ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
US9193721B2
(en)
|
2010-04-14 |
2015-11-24 |
Incyte Holdings Corporation |
Fused derivatives as PI3Kδ inhibitors
|
CN103002738A
(zh)
|
2010-05-21 |
2013-03-27 |
英特利凯恩有限责任公司 |
用于激酶调节的化学化合物、组合物和方法
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
MX2013000389A
(es)
|
2010-07-14 |
2013-03-08 |
Hoffmann La Roche |
Compuestos de purina selectivos para fosfatidilinositol 3-cinasa p110 delta, y metodods de uso.
|
CN103025725B
(zh)
|
2010-08-10 |
2015-09-16 |
安斯泰来制药有限公司 |
杂环化合物
|
UY33337A
(es)
|
2010-10-18 |
2011-10-31 |
Respivert Ltd |
DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
|
CN103298474B
(zh)
*
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
杂环化合物及其用途
|
EP2655374B1
(en)
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
AR085397A1
(es)
|
2011-02-23 |
2013-09-25 |
Intellikine Inc |
Combinacion de inhibidores de quinasa y sus usos
|
WO2012121953A1
(en)
*
|
2011-03-08 |
2012-09-13 |
The Trustees Of Columbia University In The City Of New York |
Methods and pharmaceutical compositions for treating lymphoid malignancy
|
US9108984B2
(en)
|
2011-03-14 |
2015-08-18 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
CN102719517B
(zh)
*
|
2011-03-29 |
2015-08-19 |
中国科学院上海药物研究所 |
一种检测化合物对人Ⅰ型PI3Ks抑制活性的方法
|
MY168757A
(en)
*
|
2011-05-04 |
2018-12-04 |
Rhizen Pharmaceuticals S A |
Novel compounds as modulators of protein kinases
|
CN102838600A
(zh)
*
|
2011-06-24 |
2012-12-26 |
山东亨利医药科技有限责任公司 |
苯基喹唑啉类PI3Kδ抑制剂
|
CN102838601A
(zh)
*
|
2011-06-24 |
2012-12-26 |
山东亨利医药科技有限责任公司 |
选择性磷酰肌醇3-激酶δ抑制剂
|
MX2014000648A
(es)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos.
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
TW201311663A
(zh)
|
2011-08-29 |
2013-03-16 |
Infinity Pharmaceuticals Inc |
雜環化合物及其用途
|
MX2020004502A
(es)
|
2011-09-02 |
2022-01-20 |
Incyte Holdings Corp |
Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k).
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
MY167798A
(en)
|
2011-10-03 |
2018-09-26 |
Respivert Ltd |
1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
|
US20130143902A1
(en)
*
|
2011-12-02 |
2013-06-06 |
Gilead Calistoga Llc |
Compositions and methods of treating a proliferative disease with a quinazolinone derivative
|
PT2790705T
(pt)
|
2011-12-15 |
2018-01-24 |
Novartis Ag |
Utilização de inibidores da atividade ou função de pi3k
|
WO2013134288A1
(en)
|
2012-03-05 |
2013-09-12 |
Gilead Calistoga Llc |
Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
|
AU2015252058A1
(en)
*
|
2012-03-05 |
2015-11-19 |
Gilead Calistoga Llc |
Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
|
LT2834244T
(lt)
*
|
2012-03-13 |
2016-11-10 |
Respivert Limited |
Kristalinės pi3 kinazės slopikliai
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
WO2014015523A1
(en)
*
|
2012-07-27 |
2014-01-30 |
Hutchison Medipharma Limited |
Novel heteroaryl and heterocycle compounds, compositions and methods
|
SG11201501173SA
(en)
*
|
2012-08-08 |
2015-05-28 |
Kbp Biosciences Co Ltd |
PI3Kδ INHIBITOR
|
US20140051696A1
(en)
*
|
2012-08-14 |
2014-02-20 |
Gilead Calistoga Llc |
Therapies for treating cancer
|
RU2015115631A
(ru)
|
2012-09-26 |
2016-11-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Модулирование ire1
|
JP2015533181A
(ja)
*
|
2012-10-16 |
2015-11-19 |
アルミラル・ソシエダッド・アノニマAlmirall, S.A. |
Pi3k阻害剤としてのピロロトリアジノン誘導体
|
SI2914296T2
(sl)
|
2012-11-01 |
2022-01-31 |
Infinity Pharmaceuticals, Inc. |
Zdravljenje raznih vrst raka z uporabo modulatorjev izooblik PI3-kinaze
|
KR20150079745A
(ko)
*
|
2012-11-08 |
2015-07-08 |
리젠 파마슈티컬스 소시에떼 아노님 |
Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물
|
EP2920172B1
(en)
|
2012-11-16 |
2019-12-25 |
Merck Sharp & Dohme Corp. |
Purine inhibitors of human phosphatidylinositol 3-kinase delta
|
CA2895782C
(en)
|
2012-12-21 |
2017-08-22 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
CA2895785A1
(en)
|
2012-12-21 |
2014-06-26 |
Jerry Evarts |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
US9771316B2
(en)
*
|
2013-01-21 |
2017-09-26 |
Osaka University |
Phenoxyalkylamine compound
|
WO2014128612A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
TW201522341A
(zh)
*
|
2013-03-15 |
2015-06-16 |
Respivert Ltd |
化合物
|
US9227977B2
(en)
|
2013-03-15 |
2016-01-05 |
Respivert Ltd. |
Phosphoinositide 3-kinase inhibitors
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
JP6360881B2
(ja)
|
2013-03-22 |
2018-07-18 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ
|
SG11201509842SA
(en)
|
2013-05-30 |
2015-12-30 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
AR096621A1
(es)
|
2013-06-14 |
2016-01-20 |
Gilead Sciences Inc |
Inhibidores de isómeros de la fosfatidilinositol 3-quinasa (pi3k)
|
UY35675A
(es)
*
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
WO2015014315A1
(zh)
|
2013-08-01 |
2015-02-05 |
杭州普晒医药科技有限公司 |
一种抑制剂的晶型及其制备方法和用途
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
KR20160060100A
(ko)
|
2013-09-22 |
2016-05-27 |
칼리토르 사이언시즈, 엘엘씨 |
치환된 아미노피리미딘 화합물 및 이용 방법
|
NZ718430A
(en)
|
2013-10-04 |
2021-12-24 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
JP6584391B2
(ja)
|
2013-10-10 |
2019-10-02 |
アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. |
非ホジキンリンパ腫を治療するための、hdac阻害剤単独またはpi3k阻害剤との組み合わせ
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
IN2013MU03641A
(pt)
|
2013-11-20 |
2015-07-31 |
Cadila Healthcare Ltd |
|
WO2015081127A2
(en)
|
2013-11-26 |
2015-06-04 |
Gilead Sciences, Inc. |
Therapies for treating myeloproliferative disorders
|
CN105979948A
(zh)
|
2013-12-05 |
2016-09-28 |
安塞塔制药公司 |
Pi3k抑制剂和btk抑制剂的治疗组合
|
WO2015095605A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
ES2752552T3
(es)
|
2013-12-20 |
2020-04-06 |
Gilead Calistoga Llc |
Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
|
WO2015109009A1
(en)
*
|
2014-01-15 |
2015-07-23 |
The Trustees Of Columbia University In The City Of New York |
Carbonyl erastin analogs and their use
|
EP3102238A1
(en)
|
2014-01-20 |
2016-12-14 |
Gilead Sciences, Inc. |
Therapies for treating cancers
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
CN104817559B
(zh)
*
|
2014-01-30 |
2021-05-25 |
苏州泽璟生物制药股份有限公司 |
氘代喹唑啉酮化合物以及包含该化合物的药物组合物
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
EP3110820B1
(en)
|
2014-02-28 |
2022-04-06 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
KR20220126813A
(ko)
|
2014-03-14 |
2022-09-16 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
AU2015231413B2
(en)
|
2014-03-19 |
2020-04-23 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
WO2015179772A1
(en)
|
2014-05-23 |
2015-11-26 |
Concert Pharmaceuticals, Inc. |
Deuterated phenylquinazolinone and phenylisoquinolinone compounds
|
TW201613916A
(en)
|
2014-06-03 |
2016-04-16 |
Gilead Sciences Inc |
TANK-binding kinase inhibitor compounds
|
WO2015191677A1
(en)
|
2014-06-11 |
2015-12-17 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
|
TWI681954B
(zh)
|
2014-06-12 |
2020-01-11 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
US11021467B2
(en)
*
|
2014-06-13 |
2021-06-01 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
BR112016028818A2
(pt)
|
2014-06-13 |
2017-08-22 |
Gilead Sciences Inc |
composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
|
EA201692266A1
(ru)
*
|
2014-06-13 |
2017-06-30 |
Джилид Сайэнс, Инк. |
Ингибиторы фосфатидилинозитол-3-киназы
|
SG11201609540TA
(en)
*
|
2014-06-13 |
2016-12-29 |
Gilead Sciences Inc |
Phosphatidylinositol 3-kinase inhibitors
|
MA40240B1
(fr)
|
2014-06-19 |
2019-03-29 |
Ariad Pharma Inc |
Composés hétéroaryle d'inhibition de la kinase
|
AU2015283671B2
(en)
|
2014-07-04 |
2018-07-05 |
Lupin Limited |
Quinolizinone derivatives as Pl3K inhibitors
|
CN104130261B
(zh)
*
|
2014-08-04 |
2016-03-02 |
山东康美乐医药科技有限公司 |
艾德利布的合成方法
|
AR101504A1
(es)
|
2014-08-11 |
2016-12-21 |
Acerta Pharma Bv |
Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
|
HRP20220738T1
(hr)
|
2014-08-11 |
2022-08-19 |
Acerta Pharma B.V. |
Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
|
EP3179991B1
(en)
|
2014-08-11 |
2021-10-06 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
|
WO2016023082A1
(en)
|
2014-08-12 |
2016-02-18 |
Monash University |
Lymph directing prodrugs
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
CN104262344B
(zh)
*
|
2014-08-22 |
2015-11-04 |
苏州明锐医药科技有限公司 |
艾德拉尼的制备方法
|
EP3659621A1
(en)
|
2014-09-13 |
2020-06-03 |
Novartis AG |
Combination therapies for cancer
|
CN105503877A
(zh)
|
2014-09-24 |
2016-04-20 |
和记黄埔医药(上海)有限公司 |
咪唑并哒嗪类化合物及其用途
|
MX2017003930A
(es)
|
2014-09-26 |
2017-06-30 |
Gilead Sciences Inc |
Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank.
|
BR112017006664A2
(pt)
|
2014-10-03 |
2017-12-26 |
Novartis Ag |
terapias de combinação
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
US10214537B2
(en)
|
2014-10-22 |
2019-02-26 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl amine compounds
|
WO2016064958A1
(en)
|
2014-10-22 |
2016-04-28 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
|
US10328060B2
(en)
|
2014-11-01 |
2019-06-25 |
Shanghai Fochon Pharmaceutical Co., Ltd. |
Certain protein kinase inhibitors
|
EP3031808B1
(en)
|
2014-12-09 |
2018-06-27 |
ratiopharm GmbH |
Salt of idelalisib
|
EP3048104A1
(en)
|
2015-01-20 |
2016-07-27 |
Sandoz AG |
Amorphous and crystalline forms of idelalisib and process for forming the same
|
WO2016097314A1
(en)
*
|
2014-12-19 |
2016-06-23 |
Sandoz Ag |
Amorphous and crystalline forms of idelalisib and process for forming the same
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
WO2016108206A2
(en)
*
|
2014-12-31 |
2016-07-07 |
Dr. Reddy’S Laboratories Limited |
Processes for preparation of idelalisib and intermediates thereof
|
KR101710461B1
(ko)
*
|
2015-01-16 |
2017-02-27 |
순천향대학교 산학협력단 |
키랄 2-플루오로-4-나이트로 부탄산 유도체의 제조방법
|
US9637488B2
(en)
|
2015-01-29 |
2017-05-02 |
Fuqiang Ruan |
Heterocyclic compounds as inhibitors of class I PI3KS
|
TW201639573A
(zh)
|
2015-02-03 |
2016-11-16 |
吉李德科學股份有限公司 |
有關治療癌症之合併治療
|
ES2930585T3
(es)
|
2015-02-27 |
2022-12-19 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
CR20170389A
(es)
|
2015-02-27 |
2018-01-26 |
Incyte Corp |
Sales de inhibidor de p13k y procesos de preparación
|
ME02893B
(me)
|
2015-03-04 |
2018-04-20 |
Gilead Sciences Inc |
Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina
|
US20180064714A1
(en)
|
2015-03-13 |
2018-03-08 |
Mylan Laboratories Ltd |
Process for the Preparation of Amorphous Idelalisib and its Premix
|
WO2016156240A1
(en)
|
2015-03-31 |
2016-10-06 |
Synthon B.V. |
Improved process for preparing idelalisib
|
WO2016157136A1
(en)
|
2015-04-02 |
2016-10-06 |
Mylan Laboratories Ltd |
Crystalline forms of idelalisib
|
CN106146502B
(zh)
*
|
2015-04-09 |
2019-01-04 |
上海医药工业研究院 |
艾代拉里斯的合成方法及制备中间体
|
CN104892612B
(zh)
*
|
2015-04-15 |
2017-12-19 |
上海方楠生物科技有限公司 |
一种艾德力布的无定型物及其制备方法
|
CN106146411A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
(s)-2-(1-氨基-丙基)-5-氟-3-苯基-3h-喹唑啉-4-酮的制备方法
|
CN106146352A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
Idelalisib中间体及其制备方法
|
CN106146503A
(zh)
*
|
2015-04-16 |
2016-11-23 |
上海医药工业研究院 |
一种Idelalisib的制备方法
|
GB201506786D0
(en)
*
|
2015-04-21 |
2015-06-03 |
Ucb Biopharma Sprl |
Therapeutic use
|
WO2016183060A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
CZ2015347A3
(cs)
|
2015-05-22 |
2016-11-30 |
Zentiva, K.S. |
Pevné formy 5-fluor-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]chinazolin-4-onu a jejich příprava
|
CN106279171A
(zh)
*
|
2015-06-09 |
2017-01-04 |
南京安源生物医药科技有限公司 |
一种Idelalisib的制备方法
|
WO2016209961A1
(en)
|
2015-06-23 |
2016-12-29 |
Gilead Sciences, Inc. |
Combination therapies for treating b-cell malignancies
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
US9643980B2
(en)
|
2015-07-02 |
2017-05-09 |
Genentech, Inc. |
Benzoxazepin oxazolidinone compounds and methods of use
|
SI3317284T1
(sl)
|
2015-07-02 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Spojine benzoksazepin oksazolidinona in načini uporabe
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
LT3337506T
(lt)
|
2015-08-21 |
2021-10-11 |
Morphosys Ag |
Deriniai ir jų panaudojimas
|
CZ2015575A3
(cs)
*
|
2015-08-26 |
2017-03-08 |
Zentiva, K.S. |
Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
|
WO2017040757A1
(en)
|
2015-09-02 |
2017-03-09 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
CN108137482B
(zh)
|
2015-09-08 |
2024-03-15 |
莫纳什大学 |
定向淋巴的前药
|
US10683308B2
(en)
|
2015-09-11 |
2020-06-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
MX2018003058A
(es)
|
2015-09-14 |
2018-08-01 |
Infinity Pharmaceuticals Inc |
Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
|
US20190054090A1
(en)
|
2015-10-01 |
2019-02-21 |
Gilead Sciences, Inc. |
Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
|
EP4112611A3
(en)
|
2015-10-23 |
2023-03-22 |
Navitor Pharmaceuticals, Inc. |
Modulators of sestrin-gator2 interaction and uses thereof
|
RS63125B1
(sr)
|
2015-11-03 |
2022-05-31 |
Janssen Biotech Inc |
Antitela koja se specifično vezuju za pd-1 i njihova upotreba
|
AU2016355268B2
(en)
|
2015-11-20 |
2021-08-19 |
Senhwa Biosciences, Inc. |
Combination therapy of tetracyclic quinolone analogs for treating cancer
|
HU231016B1
(hu)
*
|
2015-11-30 |
2019-11-28 |
Egis Gyógyszergyár Zrt. |
Idelalisib új polimorf és szolvát formája
|
WO2017106352A1
(en)
|
2015-12-14 |
2017-06-22 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of mthfd2 and uses thereof
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
KR20180094976A
(ko)
|
2015-12-17 |
2018-08-24 |
길리애드 사이언시즈, 인코포레이티드 |
Tank-결합 키나제 억제제 화합물
|
WO2017130221A1
(en)
*
|
2016-01-29 |
2017-08-03 |
Sun Pharmaceutical Industries Limited |
Improved process for the preparation of idelalisib
|
WO2017134607A1
(en)
|
2016-02-03 |
2017-08-10 |
Lupin Limited |
A process for the preparation of phosphatidylinositol 3-kinase inhibitor
|
CN107033145B
(zh)
*
|
2016-02-04 |
2019-11-22 |
浙江大学 |
苯并噻嗪和苯并噻二嗪类化合物及制备和应用
|
EP3423057A1
(en)
|
2016-03-04 |
2019-01-09 |
Gilead Sciences, Inc. |
Compositions and combinations of autotaxin inhibitors
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
DK3426243T3
(da)
|
2016-03-09 |
2021-07-19 |
Raze Therapeutics Inc |
3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
EP3440112A4
(en)
|
2016-04-08 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
METHOD FOR THE TREATMENT OF CANCER
|
JP2019513737A
(ja)
|
2016-04-08 |
2019-05-30 |
ギリアード サイエンシーズ, インコーポレイテッド |
がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN106074430A
(zh)
*
|
2016-06-13 |
2016-11-09 |
佛山市腾瑞医药科技有限公司 |
一种艾代拉利司泡腾片及其制备方法
|
EP3325513A4
(en)
|
2016-06-13 |
2018-12-19 |
I-Mab |
Anti-pd-l1 antibodies and uses thereof
|
US10988465B2
(en)
|
2016-06-21 |
2021-04-27 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
CA3027498A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
WO2017221272A1
(en)
*
|
2016-06-23 |
2017-12-28 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of idelalisib
|
JP7054681B2
(ja)
|
2016-06-24 |
2022-04-14 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
組合せ療法
|
KR101932146B1
(ko)
*
|
2016-07-14 |
2018-12-24 |
주식회사 바이오웨이 |
Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물
|
EP3272348A1
(en)
|
2016-07-21 |
2018-01-24 |
LEK Pharmaceuticals d.d. |
Pharmaceutical composition comprising idelalisib
|
EP3493797A1
(en)
|
2016-08-04 |
2019-06-12 |
Gilead Sciences, Inc. |
Cobicistat for use in cancer treatments
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
EP3507276B1
(en)
|
2016-09-02 |
2021-11-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
TW201813963A
(zh)
|
2016-09-23 |
2018-04-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201825465A
(zh)
|
2016-09-23 |
2018-07-16 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
TW201815787A
(zh)
|
2016-09-23 |
2018-05-01 |
美商基利科學股份有限公司 |
磷脂醯肌醇3-激酶抑制劑
|
CN109952303B
(zh)
|
2016-10-14 |
2022-10-21 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
CN106632337B
(zh)
*
|
2016-10-18 |
2018-11-20 |
湖北生物医药产业技术研究院有限公司 |
艾代拉里斯的晶型、药物组合物、制备方法和用途
|
EP3528816A4
(en)
|
2016-10-21 |
2020-04-08 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
WO2018085069A1
(en)
|
2016-11-03 |
2018-05-11 |
Gilead Sciences, Inc. |
Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
US20180141939A1
(en)
|
2016-11-22 |
2018-05-24 |
Gilead Sciences, Inc. |
Solid forms of a bet inhibitor
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
EP3559018A1
(en)
|
2016-12-23 |
2019-10-30 |
Bicyclerd Limited |
Peptide derivatives having novel linkage structures
|
US10624968B2
(en)
|
2017-01-06 |
2020-04-21 |
Bicyclerd Limited |
Compounds for treating cancer
|
KR20180093088A
(ko)
|
2017-01-24 |
2018-08-20 |
아이-맵 |
항-cd73 항체 및 이것의 사용
|
JP2020508326A
(ja)
|
2017-02-24 |
2020-03-19 |
ギリアド サイエンシズ, インコーポレイテッド |
ブルトン型チロシンキナーゼの阻害剤
|
EP3585788A1
(en)
|
2017-02-24 |
2020-01-01 |
Gilead Sciences, Inc. |
Inhibitors of bruton's tyrosine kinase
|
JP7160824B2
(ja)
|
2017-03-08 |
2022-10-25 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤、使用およびその製造のための方法
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
WO2018198131A1
(en)
|
2017-04-24 |
2018-11-01 |
Natco Pharma Limited |
Process for the preparation of amorphous idelalisib
|
US10912750B2
(en)
|
2017-04-26 |
2021-02-09 |
Navitor Pharmaceuticals, Inc. |
Modulators of Sestrin-GATOR2 interaction and uses thereof
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
CN109111447A
(zh)
|
2017-06-23 |
2019-01-01 |
中国科学院上海药物研究所 |
7-位取代吡咯并三嗪类化合物或其药学上可用的盐,及其制备方法和用途
|
CN111032678A
(zh)
|
2017-06-26 |
2020-04-17 |
拜西克尔德有限公司 |
具有可检测部分的双环肽配体和其用途
|
WO2019023468A1
(en)
|
2017-07-28 |
2019-01-31 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
JP2020529418A
(ja)
|
2017-07-31 |
2020-10-08 |
ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨークThe Trustees Of Columbia University In The City Of New York |
T細胞急性リンパ芽球性白血病を治療するための化合物、組成及び方法
|
EP3668550A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
EP3668887A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
EP4306524A2
(en)
|
2017-08-29 |
2024-01-17 |
PureTech LYT, Inc. |
Lymphatic system-directing lipid prodrugs
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
CN111093663A
(zh)
|
2017-09-07 |
2020-05-01 |
奥古斯塔大学研究所公司 |
特异性akt3激活剂及其用途
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
IL307995A
(en)
|
2017-09-22 |
2023-12-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
WO2019092253A1
(en)
|
2017-11-10 |
2019-05-16 |
Synthon B.V. |
Process for preparing idelalisib
|
WO2019126378A1
(en)
|
2017-12-19 |
2019-06-27 |
Ariya Therapeutics, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
WO2019123339A1
(en)
|
2017-12-20 |
2019-06-27 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
KR102492187B1
(ko)
|
2017-12-20 |
2023-01-27 |
인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. |
Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
|
CN112105385A
(zh)
|
2017-12-26 |
2020-12-18 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
US11701361B2
(en)
*
|
2018-01-05 |
2023-07-18 |
National Institutes Of Health (Nch), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) |
p110-delta inhibitors treat and prevent autoimmunity while sparing the ability to mount an immune response to exogenous immunogens
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
EP3740468A4
(en)
|
2018-01-20 |
2021-10-06 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHOD OF USING
|
US10988477B2
(en)
|
2018-01-29 |
2021-04-27 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
SG11202006832YA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
CN108409674A
(zh)
*
|
2018-02-09 |
2018-08-17 |
南京法恩化学有限公司 |
一种艾代拉利司中间体的制备方法
|
US10710986B2
(en)
|
2018-02-13 |
2020-07-14 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
JP7445597B2
(ja)
|
2018-02-15 |
2024-03-07 |
センワ バイオサイエンシズ インコーポレイテッド |
キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法
|
MX2020008814A
(es)
|
2018-02-27 |
2020-12-11 |
Artax Biopharma Inc |
Derivados de cromeno como inhibidores de la interaccion receptor de antigeno de celula t (tcr) - region no catalitica de la proteina citosolica de la proteina tirosina cinasa (nck).
|
CN108409740B
(zh)
*
|
2018-03-14 |
2020-05-08 |
盐城师范学院 |
一种艾代拉里斯制备方法
|
WO2019178596A1
(en)
|
2018-03-16 |
2019-09-19 |
Johnson Matthey Public Limited Company |
Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
AU2019247905B2
(en)
|
2018-04-06 |
2023-10-05 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2,2,─環二核苷酸
|
US10442799B1
(en)
|
2018-04-07 |
2019-10-15 |
Fuqiang Ruan |
Heterocyclic compounds and uses thereof
|
JP7242702B2
(ja)
|
2018-04-19 |
2023-03-20 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
CN112236428A
(zh)
|
2018-04-24 |
2021-01-15 |
默克专利股份有限公司 |
抗增殖化合物及其用途
|
CA3097774A1
(en)
|
2018-04-24 |
2019-10-31 |
Vertex Pharmaceuticals Incorporated |
Pteridinone compounds and uses thereof
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’-環二核苷酸
|
WO2019217780A1
(en)
|
2018-05-11 |
2019-11-14 |
Phosphorex, Inc. |
Microparticles and nanoparticles having negative surface charges
|
CN117304130A
(zh)
|
2018-05-14 |
2023-12-29 |
吉利德科学公司 |
Mcl-1抑制剂
|
WO2019224718A2
(en)
|
2018-05-24 |
2019-11-28 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
MX2020013630A
(es)
|
2018-06-15 |
2021-04-28 |
Anakuria Therapeutics Inc |
Analogos de rapamicina y usos de los mismos.
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
UA126421C2
(uk)
|
2018-07-13 |
2022-09-28 |
Гіліад Сайєнсіз, Інк. |
Інгібітори pd-1/pd-l1
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
CN113164419A
(zh)
|
2018-09-07 |
2021-07-23 |
皮克医疗公司 |
Eif4e抑制剂和其用途
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
CA3115088A1
(en)
|
2018-10-15 |
2020-04-23 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
EP3870597A1
(en)
|
2018-10-23 |
2021-09-01 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
CA3117336A1
(en)
|
2018-10-24 |
2020-04-30 |
Navitor Pharmaceuticals, Inc. |
Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
|
CN112955435A
(zh)
|
2018-10-24 |
2021-06-11 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
JP7460644B2
(ja)
|
2018-10-31 |
2024-04-02 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hpk1阻害剤としての置換6-アザベンゾイミダゾール化合物
|
CA3116347A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
CN113423427A
(zh)
|
2018-11-30 |
2021-09-21 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CN109593066B
(zh)
*
|
2018-12-21 |
2020-06-19 |
上海交通大学 |
一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用
|
US11174264B2
(en)
|
2019-01-23 |
2021-11-16 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
CA3129022C
(en)
|
2019-03-07 |
2023-08-01 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
US11766447B2
(en)
|
2019-03-07 |
2023-09-26 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
WO2020178770A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
EP3946462A1
(en)
|
2019-04-02 |
2022-02-09 |
BicycleTX Limited |
Bicycle toxin conjugates and uses thereof
|
SG11202110829YA
(en)
|
2019-04-05 |
2021-10-28 |
Kymera Therapeutics Inc |
Stat degraders and uses thereof
|
TWI751516B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
TW202212339A
(zh)
|
2019-04-17 |
2022-04-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
AR118720A1
(es)
|
2019-04-19 |
2021-10-27 |
Janssen Biotech Inc |
Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
|
US11453681B2
(en)
|
2019-05-23 |
2022-09-27 |
Gilead Sciences, Inc. |
Substituted eneoxindoles and uses thereof
|
SG11202113154YA
(en)
|
2019-05-31 |
2021-12-30 |
Ikena Oncology Inc |
Tead inhibitors and uses thereof
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
CN114761041A
(zh)
|
2019-07-16 |
2022-07-15 |
吉利德科学公司 |
Hiv疫苗及其制备和使用方法
|
JP2022548594A
(ja)
|
2019-09-11 |
2022-11-21 |
ビンシア・バイオサイエンシーズ・インコーポレイテッド |
Usp30阻害剤及びその使用
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CA3149557A1
(en)
|
2019-09-30 |
2021-04-08 |
Scott J. Balsitis |
Hbv vaccines and methods treating hbv
|
EP4045083B1
(en)
|
2019-10-18 |
2024-01-10 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
US20210147568A1
(en)
|
2019-10-31 |
2021-05-20 |
Forty Seven, Inc. |
Anti-cd47 based treatment of blood cancer
|
BR112022008287A2
(pt)
|
2019-11-01 |
2022-07-26 |
Navitor Pharm Inc |
Métodos de tratamento usando um modulador de mtorc1
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
KR20220128345A
(ko)
|
2019-12-05 |
2022-09-20 |
아나쿠리아 테라퓨틱스, 인코포레이티드 |
라파마이신 유사체 및 이의 용도
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
WO2021133920A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
CR20220303A
(es)
|
2019-12-24 |
2022-09-02 |
Gilead Sciences Inc |
Compuestos moduladores de la diacilglicerol quinasa
|
WO2021163064A2
(en)
|
2020-02-14 |
2021-08-19 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
EP4114529A1
(en)
|
2020-03-03 |
2023-01-11 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
BR112022018678A2
(pt)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
Degradadores de mdm2 e usos dos mesmos
|
CN113512042A
(zh)
*
|
2020-04-09 |
2021-10-19 |
成都赜灵生物医药科技有限公司 |
取代喹唑啉-4-酮类化合物及其制备方法和用途
|
US20240043427A1
(en)
|
2020-05-01 |
2024-02-08 |
Gilead Sciences, Inc. |
Cd73 compounds
|
JP2023525383A
(ja)
*
|
2020-05-16 |
2023-06-15 |
フォチョン・バイオサイエンシーズ・リミテッド |
キナーゼ阻害剤としての化合物
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CA3186504A1
(en)
|
2020-08-17 |
2022-02-24 |
Stephen J. Blakemore |
Bicycle conjugates specific for nectin-4 and uses thereof
|
CN111840297B
(zh)
*
|
2020-08-24 |
2023-06-16 |
天津济坤医药科技有限公司 |
艾代拉里斯在制备用于治疗肝纤维化疾病的药物中的应用
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
US20240059789A1
(en)
|
2021-01-28 |
2024-02-22 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
JP2024506858A
(ja)
|
2021-02-02 |
2024-02-15 |
リミナル・バイオサイエンシーズ・リミテッド |
Gpr84アンタゴニストおよびその使用
|
CA3206501A1
(en)
|
2021-02-02 |
2022-08-11 |
Shaun Abbott |
Gpr84 antagonists and uses thereof
|
WO2022174269A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用FLT3L—Fc融合蛋白之方法
|
US11926628B2
(en)
|
2021-06-23 |
2024-03-12 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
IL309378A
(en)
|
2021-06-23 |
2024-02-01 |
Gilead Sciences Inc |
DIACYLGLYERCOL KINASE MODULATING COMPOUNDS
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
US20230134932A1
(en)
|
2021-08-25 |
2023-05-04 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
EIF4E inhibitors and their uses
|
WO2023076983A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
US11919869B2
(en)
|
2021-10-29 |
2024-03-05 |
Gilead Sciences, Inc. |
CD73 compounds
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
TW202345901A
(zh)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024015741A1
(en)
|
2022-07-12 |
2024-01-18 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|